Furthermore, SSc patients with both detectable IL-17A and high IL-6 levels exhibit more pronounced lung impairment and increased PAH prevalence than those with undetectable IL-17A and low IL-6 [130]. Here, IL17A is linked to pulmonary arterial hypertension.